28448-12-6

Basic information

• Product Name: 3-quinolinecarbonitrile, 1,2-dihydro-4-methyl-2-oxo-
• Synonyms: 3-quinolinecarbonitrile, 1,2-dihydro-4-methyl-2-oxo-;4-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile
• CAS NO: 28448-12-6
• Molecular Formula: C₁₁H₈N₂O
• Molecular Weight: 184.19402
• Mol File: 28448-12-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: >300 °C
• Boiling Point: 399.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• PKA: 9.76±0.70(Predicted)
• CAS DataBase Reference: 3-quinolinecarbonitrile, 1,2-dihydro-4-methyl-2-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-quinolinecarbonitrile, 1,2-dihydro-4-methyl-2-oxo-(28448-12-6)
• EPA Substance Registry System: 3-quinolinecarbonitrile, 1,2-dihydro-4-methyl-2-oxo-(28448-12-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 28448-12-6(Hazardous Substances Data)

Usage

General Description

3-quinolinecarbonitrile, 1,2-dihydro-4-methyl-2-oxo- is a chemical compound with the molecular formula C10H8N2O. It is a derivative of quinoline and is commonly used in the pharmaceutical industry for the synthesis of various pharmaceuticals and agrochemicals. This chemical has also been studied for its potential biological and pharmacological activities, such as antimicrobial and anticancer properties. Its structure and properties make it a valuable intermediate in the production of a wide range of organic compounds, making it an important building block in chemical synthesis.

Upstream product

• 551-93-9 2-aminoacetophenone 
• 105-56-6 ethyl 2-cyanoacetate 
• 1016641-95-4 C₁₁H₁₀N₂O₂ 
• 613-89-8 2-Aminoacetophenone 

Downstream Products

• 491-35-0 C₆H₄NCH₂CHCCH₂ 
• 101617-94-1 2?chloro?3?cyano?4?methylquinoline 
• 209617-32-3 (E)-4-(2-anilinoethenyl)-2-oxo-1,2-dihydro-quinoline-3-carbonitrile 
• 178617-78-2 3-Amino-4-methyl-thieno[2,3-b]quinoline-2-carboxylic acid phenylamide 
• 178617-79-3 3-Amino-4-methyl-thieno[2,3-b]quinoline-2-carboxylic acid (4-methoxy-phenyl)-amide 
• 178617-81-7 3-Amino-4-methyl-thieno[2,3-b]quinoline-2-carboxylic acid (4-phenyl-thiazol-2-yl)-amide 

Relevant articles and documents

Enantioselective Direct Vinylogous Allylic Alkylation of 4-Methylquinolones under Iridium Catalysis

The first enantioselective vinylogous allylic alkylation of 4-methylquinolones has been developed. This iridium-catalyzed reaction introduces an allyl group at the γ-position of 4-methyl-2-quinolones with exclusive branched selectivity and an excellent level of enantioselectivity. This in turn allows for the enantioselective synthesis of γ-allylquinolines and related nitrogenous heterocycles. This is the first application of 4-methylquinolones in an enantioselective transformation.

Polycyclic Aromatic Alkaloids, III: Synthesis of Perlolidine

-

Pyridone derivative and application thereof in preparation of medicine for preventing and/or treating tuberculosis caused by Mycobacterium tuberculosis

The invention provides a pyridone derivative and application thereof in preparation of a medicine for preventing and/or treating tuberculosis caused by mycobacterium tuberculosis, which belong to the field of pharmacy. The structure of the pyridone derivative is shown as a formula (I). Experimental results show that the pyridone derivative provided by the invention can specifically inhibit the activity of mycobacterium tuberculosis, has small toxic and side effects, can be used for preparing a medicine for resisting mycobacterium tuberculosis, can also be used for preparing a medicine for preventing and/or treating tuberculosis, and a new choice is provided for medicines for treating tuberculosis (especially drug-resistant tuberculosis).

QUINOLINONE DERIVATIVES

HIV inhibitory compounds of formula (I) including the stereoisomeric forms thereof, the pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof; wherein R1 is cyano; R2 is H, C1-6alkyl, trifluoromethyl, amino, mono- or di-C1-6alkylamino, C1-6alkylamino wherein the C1-6alkyl group can be substituted; X1 is CH or N; R3 is phenyl or pyridyl, each unsubstituted or substituted; R4 is H, C1-6alkyl, (C1-6alkylcarbonyla mino)C1-6alkyl-, Ar, potionally substituted thienyl, furanyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrazolyl, imidazolyl, triazo lyl, oxazolyl, thiazolyl, halo, trifluoromethyl, hydroxy, C1-6alkyloxy, -OPO(OH)2, amino, aminocarbonyl, cyano, -Y1-R6, -Y1-Alk-R6, or -Y1-Alk-Y2-R7; R5 is H, halo, hydroxy or C1-6alkyloxy; or R4 and R5 form -O-CH2-O-; Y1 is O or NR8; Y2 is O or NR9; Alk is bivalent C1-6alkyl; R6 is pyrrolidinyl, piperidinyl, morpho linyl, piperazinyl, 4-C1 -6alkylpiperazinyl, 4-(C1-6alkylcarbonyl)piperazinyl, pyridyl, or imidazolyl; R7 is H, C1-6alkyl, hydroxyC1 -6alkyl, C1-6alkylcarbonyl; R8 and R9 are H or C1-6alkyl; Ar is optionally substituted phenyl; pharmaceut ical compositions comprising the above compounds (I) as active ingredient.